4D pharma plc (LBPS)

Overview

4D pharma plc, along with its subsidiaries, is engaged in the innovative research, development, and production of live biotherapeutic products. With a focus on treating various medical conditions, the company is advancing numerous development programs aimed at answering the needs within the healthcare community. Key areas of concentration include gastrointestinal disorders, immuno-oncology, respiratory conditions, and central nervous system diseases. The company also boasts a partnership with Merck & Co., Inc., facilitating a clinical trial that explores the therapeutic potential of combining Keytruda with one of its products in treating solid tumors. Founded in 2014 and headquartered in Leeds, the United Kingdom, 4D pharma plc was previously recognized as Schosween 18 Limited.

Products and Services

• Blautix: Designed for treating irritable bowel syndrome, Blautix aims to restore the balance of gut microbiota, potentially alleviating symptoms associated with gastrointestinal disturbances.
• Thetanix: Targeting pediatric Crohn’s disease, Thetanix is formulated to address this challenging inflammatory bowel condition, focusing on improving quality of life for young patients.
• MRx0518: An immuno-oncology product, MRx0518 is undergoing development for treating solid tumors and has a designated collaboration with Merck to test its efficacy in combination with Keytruda.
• MRx0573: Another candidate in the immuno-oncology sector, MRx0573 is a strategic component in the pipeline aimed at solid tumor treatment.
• MRx1299: This product targets specific mechanisms within solid tumors, contributing to the overall arsenal of cancer therapies in development.
• MRx-4DP0004: Focused on respiratory health, particularly for asthma and COVID-19, MRx-4DP0004 aims to modulate the immune response within the respiratory tract.
• MRx0005: In the realm of central nervous system products, MRx0005 is under evaluation for neurodegenerative disorders, seeking to enhance patient outcomes in cognitive health.
• MRx0029: This product is also part of central nervous system initiatives, focusing on therapeutic interventions for neurodegenerative disease management.
• Platform Products: The company is developing a set of platform products that include vaccines and treatments for autoimmune diseases, diversifying its therapeutic offerings against a range of health challenges.